Related Experiment Videos
Attention-deficit/hyperactivity disorder pharmacogenomics.
1Neuropsychiatric Institute and David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California 90095, USA. jmcgough@mednet.ucla.edu
Biological Psychiatry
|June 14, 2005
Summary
Pharmacogenomics shows promise for tailoring attention-deficit/hyperactivity disorder (ADHD) treatments. However, current research has limitations, necessitating larger, prospective studies for personalized ADHD medication strategies.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Medications for attention-deficit/hyperactivity disorder (ADHD) show efficacy but have variable patient adherence and tolerability.
- Pharmacogenomics offers a potential solution by identifying genetic variations to personalize ADHD treatment regimens and improve long-term adherence.
Purpose of the Study:
- To review existing studies in ADHD pharmacogenomics.
- To assess current knowledge and inform future research directions in the field.
Main Methods:
- A systematic review of twelve identified studies on ADHD pharmacogenomics.
- Analysis focused on candidate genes (e.g., DAT1, DRD4, COMT) and their association with methylphenidate response.
- Inclusion of one study employing quantitative trait analyses in a genome-wide scan.
Main Results:
- Most studies investigated candidate genes, with DAT1 being the most frequently examined, yielding inconsistent findings regarding symptom reduction.
- Other genes such as DRD4, DRD5, DBH, 5HTT, SNAP-25, and COMT were also explored.
- Preliminary studies were characterized by small sample sizes, varied designs, retrospective data, and a narrow focus on symptom response.
Conclusions:
- While interest in ADHD pharmacogenomics is growing, current evidence is limited.
- Future research requires large, prospective trials assessing multiple medications and comprehensive pharmacodynamic/pharmacokinetic outcomes for effective personalized ADHD treatment.